8 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 6 Phase 2, 3 Phase 3, 2 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Terminated 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
| Phase 4 | 1 | Active not recruiting 1 |
Follow avacincaptad pegol: new trials by email Literature Review of avacincaptad pegol trials Research Report on avacincaptad pegol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration avacincaptad pegol - Geographic Atrophy, Age-Related Macular Degeneration | Phase 4 | Active not recruiting | Astellas Pharma Inc | 17 | 2025-07-08 | 2026-10-30 |
| Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy avacincaptad pegol - Geographic Atrophy, Age-Related Macular Degeneration | Phase 3 | Completed | Astellas Pharma Global Development, Inc. | 278 | 2022-09-26 | 2026-05-18 |
| A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) Avacincaptad Pegol, Sham - Geographic Atrophy, Macular Degeneration | Phase 3 | Completed | IVERIC bio, Inc. | 448 | 2020-06-22 | 2025-10-21 |
| ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) Zimura, Eylea - Idiopathic Polypoidal Choroidal Vasculopathy | Phase 2 | Withdrawn | Ophthotech Corporation | 2018-11-01 | 2024-02-21 | |
| Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) avacincaptad pegol, Sham - Stargardt's Macular Dystrophy | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 121 | 2018-01-12 | 2026-04-15 |
| ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) Avacincaptad Pegol, Lucentis - Neovascular Age-related Macular Degeneration | Phase 2 | Completed | Ophthotech Corporation | 64 | 2017-10-11 | 2025-06-10 |
| Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD Avacincaptad Pegol, Avastin, Lucentis - Neovascular Age-Related Macular Degeneration | Phase 2 | Terminated | IVERIC bio, Inc. | 1 | 2016-10-20 | 2025-03-13 |
| Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Avacincaptad Pegol, Sham - Geographic Atrophy, Dry Age-Related Macular Degeneration | Phase 2 / Phase 3 | Completed | IVERIC bio, Inc. | 286 | 2015-12-15 | 2025-06-10 |
| A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) Avacincaptad Pegol - Idiopathic Polypoidal Choroidal Vasculopathy | Phase 2 | Completed | Ophthotech Corporation | 4 | 2015-03-12 | 2025-03-20 |
| A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration Avacincaptad Pegol - Dry Age-Related Macular Degeneration | Phase 1 | Completed | Ophthotech Corporation | 47 | 2009-07-16 | 2025-03-10 |
| ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration Avacincaptad Pegol - Neovascular Age-Related Macular Degeneration | Phase 1 | Completed | Ophthotech Corporation | 60 | 2008-10-16 | 2025-03-10 |
Geographic Atrophy (4) · Macular Degeneration (3) · Polypoidal Choroidal Vasculopathy (2) · Stargardt Disease (1)
Ophthotech Corporation (5) · IVERIC bio, Inc. (3) · Astellas Pharma Global Development, Inc. (2) · Astellas Pharma Inc (1)
United States (9) · Hungary (5) · Israel (4) · Latvia (4) · Croatia (3) · Czechia (3) · France (3) · Germany (3) · Italy (3) · Spain (3) · Argentina (2) · Australia (2) · Austria (2) · Belgium (2) · Brazil (2)
PMID 37314061, PMID 30957581, PMID 32882310, PMID 37696275, PMID 39538001, PMID 41407269
2015 (1), 2017 (1)